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A convenient approach to an advanced
intermediate toward the naturally occurring,
bioactive 6-substituted 5-hydroxy-
4-aryl-1H-quinolin-2-ones†
Sebastián O. Simonetti, Enrique L. Larghi* and Teodoro S. Kaufman*
5-Hydroxy-4-aryl-3,4-dihydro-1H-quinolin-2-ones are a small family of natural products isolated from
fungal strains of Penicillium and Aspergillus. Most of its members, which are insecticides and anthelmin-
tics, carry an isoprenoid C-6 side chain. The synthesis of a 6-propenyl-substituted advanced intermediate
for the total synthesis of these natural products is presented in this paper. This was achieved through the
stereoselective construction of a β,β-diarylacrylate derivative from 6-nitrosalicylaldehyde, using a Wittig
olefination and a Heck–Matsuda arylation, followed by a selective Fe0-mediated reductive cyclization.
Installation of the 6-propenyl side chain was performed by 5-O-allylation of the heterocycle, followed by
Claisen rearrangement and conjugative migration of the allyl double bond, as the key steps. The Grubbs
II-catalyzed olefin cross metathesis of the 6-allyl moiety with 2-methylbut-2-ene to afford a precursor of
peniprequinolone is also reported.
Introduction
The quinoline core is a privileged heterocyclic structure found
in many natural products and bioactive compounds.1 Interest-
ingly, filamentous fungi have been the source of relatively few
quinoline derivatives;2 however, certain strains of Penicillium
and Aspergillus produce 5-hydroxy-4-aryl-3,4-dihydro-1H-quino-
lin-2-ones, including those bearing a C-6 alkyl/alkenyl side
chain, which form a unique new family of natural products.
Thus, the yaequinolones B–F, J1 and J2 (1a–1g, Fig. 1)3a
were isolated from Penicillium sp. FKI-2140, along with nine
related compounds, including peniprequinolone (1h) and the
penigequinolones A and B (1i and 1j).3b–g The cytotoxic and
antifungal3c 1h, previously obtained from P. simplicissimum
and P. namyslowskii,3f was also found to be a nematicidal anti-
biotic against the root-lesion nematode Pratylenchus penetrans.3d
The diastereomeric 1i and 1j, pollen growth inhibitors and
nematicidal against Pratylenchus penetrans,3d were also isolated
from Penicillium sp. No. 410 and P. scabrosum.3g On the other
hand, the related aspoquinolones A–D (1k–n) are cytotoxic and
antiproliferative on some cancer cell lines.2a
This research also afforded the yaequinolones A1 and A2
(2a,b) and the quinolinones A and B (2c,d).3c,d,4a Heterocycles
2a and 2b have been previously obtained from a P. janczewskii
strain of marine origin,3b,4b,c whereas 2c and 2d were originally
obtained from P. simplicissimum and found to behave as
insecticidal antibiotics,3c being toxic against various cancer
cell lines.3b
In addition, two strains of Aspergillus were the source of the
aflaquinolones A–D (4a–d) and the aflaquinolones E–G, which
lack the 4′-OMe group.5a Some aflaquinolones have also been
obtained from the endophyte A. nidulans MA-143, together
with 1h and the aniduquinolones A–C. The latter, analogous
to yaequinolones C and F (1b and 1e),5b are lacking the 4′-OMe
group.
More recently, the unusual 22-O-(N-methyl-L-valynyl) ester
of aflaquinolone B (4e) and its epimer 4f were isolated from
the mycelia of Aspergillus sp. XS-20090B15, together with the
aflaquinolones A and D (or a diastereomer of it).5c Compound
4f exhibited remarkable anti-respiratory syncytial virus activity.
Genomic and biosynthetic studies suggested that this
family may derive from anthranilic acid and phenylalanine or
tyrosine, through the intermediacy of diketobenzodiazepines,2a,3d
such as 3a,b, which have been isolated concomitantly.4c The
latter undergo ring opening and re-cyclization to afford the
basic 3,4-dihydro-1H-quinolin-2-one core, through the 4-phenyl-
quinoline viridicatin as an intermediate.5d–g Next, O-methyl-
ation of the –OH moieties, installation of the C-4 and C-5 –OH
groups, attachment of the C-6 side chains and further
Instituto de Química Rosario (IQUIR, CONICET-UNR) and Facultad de Ciencias 
Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 
S2002LRK Rosario, Argentina. E-mail: kaufman@iquir-conicet.gov.ar;
Fax: +54-341-4370477; Tel: +54-341-4370477
† Electronic supplementary information (ESI) available: Selected spectra of inter-
mediates and the final product. See DOI: 10.1039/c5ob02680f
Hence, our approach to the natural products (5, Scheme 1)
relied on a retrosynthetic analysis involving strategies of types
(d) and (e). The C-6 substituent of the target was disconnected
at the double bond level, considering that the side chains
could be installed by olefin cross-metathesis of a 6-vinyl quino-
lin-2-one. It was also inferred that the cis-3,4-diol monoether
system could result from dihydroxylation of a Δ3,4 precursor,10
and selective alkylation of the less hindered alcohol, revealing 6
to be the suitable common advanced key intermediate sought.
Generally, β-substituted styrenes are less costly and easier
to prepare than their styrene counterparts, and also more
stable and less prone to undergo homodimerization or spon-
taneous polymerization.11a–d Therefore, it was considered
installing a 6-propenyl side chain (6a), taking advantage of the
5-OH group.11e
Fig. 1 Chemical structures of representative naturally-occurring 6-substituted 5-hydroxy-4-aryl-1H-quinolin-2-ones and their congeners. Except
for 2a and 2d, it is assumed that the heterocycles bear a cis-3,4-dioxygenated pattern and exhibit the same 3S,4S configuration.
Fig. 2 Most relevant general strategies for the synthesis of 4-substi-
tuted 1H-quinolin-2-ones.
functionalization would explain their diversity.5h The natural 
products are optically active, displaying a 3S,4S configuration.3b,5a
Ectoparasiticidal and antiproliferative preparations contain-
ing some of these heterocycles have been patented.6a–e 
However, synthetic activity in this area has been very scarce.6f,g
In pursuit of a common general synthetic approach to the 
members of this family of natural products, herein we report a 
concise route to a potential common key intermediate for the 
6-substituted 5-hydroxy-4-aryl-3,4-dihydro-1H-quinolin-2-ones, 
bearing the fundamental structural motif 1. In addition, the 
synthesis of a peniprequinolone (1h) derivative, lacking the 
3,4-glycol monomethyl ether feature, is disclosed.
Results and discussion
There are five main synthetic approaches to 4-alkyl/aryl-substi-
tuted 1H-quinolin-2-ones (Fig. 2), which relate to the single 
bond involved in closing the heterocyclic ring.7a These consist 
of types (a),7b–g (b),8a (c),8b (d),8c,d and (e).8e,f However, strate-
gies of types (b) and (c) are unsuitable for the synthesis of 
5-hydroxy/alkoxy substituted heterocycles, mainly due to their 
narrow scope and difficulties to access the starting materials, 
whereas type (a) demands starting from 1,2,4-substituted ben-
zenoids,9a–g to block the preferred alternative cyclization 
mode, en route to 7-hydroxy/alkoxy derivatives.9h,i
carbethoxymethylene triphenylphosphorane, which gave 88%
of cinnamate 14a, as a 4 : 1 mixture of geometric (E : Z)
isomers, according to the 1H NMR integration.
Installation of the 4-methoxyphenyl moiety was accom-
plished by means of a Heck reaction15 of 14a with 4-iodo-
anisole (15) in refluxing Et3N, under Pd(OAc)2 catalysis, which
provided the β,β-diphenylacrylate 16 as a 86 : 14 (1H NMR inte-
gration) mixture of geometric isomers, in 60% combined yield.
The Z-configuration of the main isomer of 16 was ascertained
with the aid of nOe experiments, which revealed mutual signal
enhancement between the vinylic proton next to the carboxy-
late ester and the aromatic protons located meta to the 4′-
methoxy group (2′-H and 6′-H).
In order to insert the required nitrogen atom and properly
activate the β,β-diphenylethylene derivative toward cyclization,
the ester 16 was saponified (90%) and the resulting carboxylic
acid 17 was reacted with tosyl isocyanate in the presence of
Et3N, furnishing the tosylimide derivative 18 (95%).
8e,16 Un-
fortunately, however, all attempts to cyclize 18 under Pd catalysis,
Scheme 1 General retrosynthetic analysis of the natural products 5.
Target heterocycles 6 and 6a as advanced key intermediates.
Scheme 2 Attempted synthesis of intermediates 19 from salicylalde-
hyde (12).
Conjecturing that the heterocyclic ring could be accessed by 
lactamization of a β,β-diarylacrylate with a suitably placed 
amine attached to the aromatic ring [type (d)],12a,b or by N-ary-
lation [type (e)],8e,f,12c,d revealed 7 to be a potential precursor of 
6a (route a). In turn, it was conceived that β,β-diarylacrylate 7 
could be obtained from a cinnamic acid derivative (8).13a,b
On the other hand, it was supposed that compound 9, 
which could also be made available from cinnamate 8, might 
also be considered a suitable precursor of 6a (route b); 
however, previous findings on the resistance of certain 1H-qui-
nolin-2-ones to undergo the Heck reaction on C-412c discour-
aged exploration of this alternate route as the first choice. 
Further examination of 8 uncovered a precursor aldehyde 
moiety14 and unveiled a phenol, suggesting aldehydes 10, 
obtainable from commercially available phenols 11, to be suit-
able starting materials.
The type (e) approach was explored first. Therefore, salicyl-
aldehyde (12) was subjected to a Williamson etherification 
with benzyl chloride in absolute EtOH, employing K2CO3 as a 
base, which afforded 99% of benzyl ether 13 (Scheme 2). In 
turn, the aldehyde 13 was exposed to a Hörner–Wadsworth–
Emmons (HWE) reaction with (MeO)2P(O)CH2CO2Me, furnish-
ing 55% of cinnamate 14. However, better results were 
obtained when 13 was subjected to a Wittig olefination with
p-anisidine24d to Pd(OAc)2 catalysis, furnished 80% of the
β,β-diarylacrylate 26.
An nOe experiment, revealing mutual signal enhancement
between the vinylic proton of the acrylate motif (δ 6.45, singlet)
and the neighbouring aromatic protons of the 4-methoxyaryl
moiety (δ 7.33, d, J = 8.8 Hz), established the Z geometry of 26.
This outcome of the Heck–Matsuda reaction, analogous to that
of the Heck arylation,25 has been explained mechanistically.26
Next, the one pot benzyl ether group hydrogenolysis with a
concomitant reduction of the nitro moiety to the corres-
ponding amino-derivative 29 and further cyclization toward 27
was attempted on 26. However, when the Pd-mediated catalytic
hydrogenation was attempted under a variety of conditions,27
it exhibited several unforeseen problems, which ranged from
partial reduction of the nitro group to concomitant hydrogen-
ation of the acrylate double bond, despite being sterically
hindered.
Thus, the hydrogenation with 10% Pd/C in MeOH at room
temperature produced equal amounts of 19 and its debenzy-
lated analog 27 in 30% combined yield (Table 1, entry 1),
whereas the reaction proceeded more sluggishly in EtOH
(entry 2).
However, addition of Et3N to the ethanolic medium pro-
voked the hydrogenation of the nitro moiety and the sub-
sequent cyclization, but also the debenzylation and
hydrogenation of the Δ3,4 double bond, furnishing 61% of 28
(entry 3). On the other hand, when the reaction was run in
refluxing toluene, a 30 : 70 mixture of cyclized (19) and de-
benzylated and uncyclized products (29) was obtained in 25%
combined yield (entry 4).
Considering the above results, a stepwise strategy was
devised, prioritizing the sequential nitro group reduction–
cyclization toward 19. Unfortunately, SnCl2 in EtOH
28 also gave
40% of a 37 : 63 mixture of 19 and 29 when the reaction was
Scheme 3 Synthesis of the intermediate 26 from 3-nitrophenol (21).
with Cu(OAc)2 as a co-catalyst and aerobic conditions,8e 
met with failure, resulting in complete degradation of the 
tosylimide.
It seems likely that the lability of 18 toward the cyclization 
conditions that would lead to 19a may be related to its struc-
ture, because exposure of the β,β-diphenylacrylic acid tosyli-
mide to the same cyclization conditions afforded 70% of the 
expected 4-phenyl-1H-quinolin-2-one, completely agreeing with 
the literature.
In view of this outcome, the copper-catalyzed cyclization of 
amide 20 was explored as an alternative. Amidation of ester 16 
with ammonia met with failure;17a therefore, the acid 17 was 
amidated with NH4Cl/TsCl supported on a silica gel, under 
Et3N promotion, affording 80% of 20.17b However, exposure of 
the amide to various copper-mediated C–H activation proto-
cols8f,18 resulted in complete recovery of the starting amide 20.
Therefore, the attention changed to a type (d) strategy, 
which involves forming the Ar–N bond prior to cyclization 
or entails using starting materials which already contain the 
heteroatom.8d,e
3-Nitrophenol (21) was selected as the new starting 
material, considering that the nitro moiety could mask the 
required amino group during the initial stages and that it 
could be engaged in a one-pot reductive cyclization (7 → 6),19 
under conditions that could also result in the removal of the 
protecting benzyl ether.
With these ideas in mind, compound 21 was subjected to a 
Duff formylation with hexamethylenetetramine (HMTA) in 
F3CCO2H at 110 °C for 12 h, affording the expected aldehyde 
22 as an 85 : 15 mixture with its isomer 22a, in 54% combined 
yield. Notably, previous syntheses of 22 took place with rather 
lower yields.20 In turn, phenol 22 was subjected to a William-
son etherification with BnCl in refluxing EtOH, employing 
K2CO3 as a base, to give 23 in almost quantitative yield 
(Scheme 3).
Introduction of the two-carbon moiety required for building 
the 1H-quinolin-2-one feature was performed by means of a 
Wittig reaction21 with ethyl(triphenyl-λ5-phosphanylidene)-
acetate, affording 88% of cinnamate 24.22 The coupling con-
stants of the vinylic hydrogens ( J = 16.2 Hz) unequivocally 
established the stereochemistry of 24 as E.
When the Heck conditions leading to 16 were applied to 24, 
the corresponding β,β-diarylacrylate was obtained in 55%
yield, confirming previous observations where the reaction was 
found to lose efficiency when attempting to introduce elec-
tron-rich aryl groups.23 This suggested the need for an alter-
nate strategy.
Although alternative Heck protocols were available,24a the 
Heck–Matsuda reaction seemed a suitable transformation to 
fulfil our expectations, since it is apparently devoid of this 
drawback.24b–e Recent examples from the laboratory of Correia 
were encouraging; furthermore, the p-anisidine reagent 
required for introducing the 4-methoxyphenyl moiety is readily 
available, and is several times less expensive than p-iodoanisol.
Thus, exposure of a refluxing methanolic mixture of cinna-
mate 24 and the diazonium tetrafluoroborate 25, derived from
delight, no other alkylation products were observed. Sub-
mission of ether 31 to the projected Claisen rearrangement
took place under microwave irradiation in 1,2-dichloro-
benzene, affording 75% of the desired 6-allyl derivative 32.
Table 1 Optimization of the reductive cyclization of 26
Entry Reducing system Solvent Time (h) Temp. (°C) Yield (%) 19/27/28/29
1 H2, 10% Pd/C MeOH 2 rt 30 50/50/0/0
2 H2, 10% Pd/C EtOH 3 rt 15 —
3 H2, 10% Pd/C EtOH
a 3 rt 61 0/0/100/0
4 H2, 10% Pd/C PhMe 2 110 25 30/0/0/70
5 SnCl2 EtOH 17 rt 40 37/0/0/63
6 SnCl2 EtOH 17 Reflux 35 0/0/0/100
7 Fe0, CaCl2 EtOH 0.5 Reflux Decomp. —
8 Fe0 (8 equiv.) AcOH 14 110 74 100/0/0/0
a Et3N was added.
Scheme 4 Construction of the 2-quinolonic ring and synthesis of 32.
performed at room temperature (entry 5), and only 29 was iso-
lated (35%) when the transformation was carried out under 
reflux (entry 6). The formation of 29 under these different con-
ditions ruled out employing SnCl2 as the reducing agent for 
this step.
On the other hand, the use of the Fe/CaCl2 system in reflux-
ing EtOH29a unexpectedly furnished solely degradation pro-
ducts (entry 7). However, to our delight, exposure of 26 to 
elemental iron powder in glacial AcOH at 110 °C resulted in 
the selective reduction of the nitro moiety to 30 and sub-
sequent lactamization, cleanly affording 74% of 19 as the sole 
product (entry 8).29b–d
With the core 1H-quinolin-2-one 19 in hands (Scheme 4), 
the next steps were devoted to the installation of the C-6 β-pro-
penyl side chain. Therefore, proper conditions were sought for 
the selective debenzylation of 19 and O-allylation of 27.30a
The results of Table 1 seemed to confirm the literature 
observations that characterized the selective debenzylation of 
aryl benzyl ethers in the presence of C–C double bonds as 
‘difficult’.30b However, in the case of 19, after several trial and 
error attempts under different conditions, it was learned that 
10% Pd/C in a cold 1 : 1 (v/v) EtOH–EtOAc solvent mixture 
under an atmospheric pressure of hydrogen was an effective 
system for selectively cleaving the benzyl ether without 
affecting the Δ3,4 double bond.30c Under these conditions, 
89% of 27 was reliably obtained after 4 h.
Next, the selective O-allylation of the phenol moiety of 27 was 
undertaken. Literature precedents suggested that the ambident 
anion at N-1–C-2 is a potentially competitive reaction site30a,31 
and that, in principle, the O-allylation should predominate.30a
In fact, when compound 27 was subjected to a conventional 
Williamson allylation, with K2CO3 in EtOH at 60 °C, 65% of 
the expected O-allyl derivative 31 was obtained and, to our
Interestingly, the 6-allyl 1H-quinolin-2-ones have elicited
great synthetic and pharmaceutical interest, having also been
used as intermediates toward drugs for treating cardiac dis-
eases, protecting against UV rays, scavenging active oxygen
species, and inhibiting enzymes as well as lipid
peroxidation.32
The acquisition of compound 32 enabled the proposed syn-
thesis of 33, a peniprequinolone (1h) analog lacking its 3,4-
glycol monoether feature (Scheme 5). This target was con-
veniently achieved in 77% yield by olefin cross metathesis of
32 with 2-methylbut-2-ene, under Grubbs II catalyst promotion
in refluxing CH2Cl2.
33
However, the achievement of the second and main objective
proved more difficult. Unexpectedly, the isomerization of the
terminal double bond of 32 toward 34 proved to be challenging
under a wide range of catalysts and conditions.
The attempts employing stressed Grubbs-II catalyst (MeOH,
60 °C, 3 h), RhCl3·3H2O (EtOH, rt, 7 h), Pd(PPh3)2Cl2 (CHCl3,
40 °C, 4 h) and [(C6H5)3P]3Ru(CO)(Cl)H (PhMe, 90 °C, 18 h)
met with failure, and an unexpected complete degradation of
the starting material with a concomitant production of
complex mixtures of unidentifiable products was invariably
observed. This was somewhat reminiscent of the outcome of a
similar attempt at allyl group isomerization during the syn-
thesis of an intermediate for fumimycin.34
We speculated that under the isomerization conditions,
either the free phenol or the amide of 34 (or even its less con-
tributing phenolic lactim moiety) could lead to structural
destabilization of the product, by acid–base or metal-promoted
tautomerization to quinone methides, which in turn could
undergo degradation.
It has been proposed that quinone methides are formed as
intermediates during Pd-catalyzed reactions of 2-vinyl phenols
and other conditions involving easily protonable or otherwise
reactive benzylic positions and properly placed phenolic
groups.35 These are highly reactive species, capable of under-
going different reactions, including polymerization. Further
after observing that 34 was fully recovered after exposure to
KtBuO in THF for 12 h at room temperature, it was conceived
that perhaps the organometallic intermediates and not the iso-
merized product 34 may be the ones that trigger the degra-
dation of the heterocycle.
In light of this situation, it was decided to block the poss-
ible involvement of the lactam moiety of 32 in the tautomeriza-
tion reaction, through its protection as the N-Boc derivative
35.36 This was accomplished in 63% yield with Boc2O and
Et3N in CH2Cl2. Surprisingly, however, the isomerization
remained challenging, as compound 35 was also reluctant to
cleanly afford the isomerized product. Its exposure to
[(C6H5)3P]3Ru(CO)(Cl)H in toluene for 17 h at 70 °C did not
afford any isomerized product, whereas heating at 90 °C for
24 h furnished the expected heterocycle 36, albeit contami-
nated with PPh3O, which turned difficult to remove chromato-
graphically. On the other hand, the use of Pd(PPh3)2Cl2
(CHCl3, rt, 3 h) gave a mixture of unidentifiable products.
Finally, our expectations were met when exposure of 35 to
RhCl3·3H2O in absolute EtOH resulted in the smooth isomeri-
zation of the allyl moiety, furnishing 50% of the sought
product 36, when the reaction was left for 31 h at room temp-
erature. Analysis of its 1H NMR spectrum, which exhibited
signals at δ 6.19 (dd, J = 6.3 and 15.7 Hz, CH3–CHvCH–Ar)
and δ 6.36 (d, J = 15.7 Hz, CH3–CHvCH–Ar), unequivocally
confirmed the E-stereochemistry of the β-methylstyrene
unit in 36.
Conclusions
We have developed a convenient approach to an advanced
common key intermediate for the synthesis of relevant
members of the 6-substituted 5-hydroxy-4-aryl-3,4-dihydro-1H-
quinolin-2-one family of natural products. The synthetic strat-
egy entailed building and cyclization of a substituted β,β-diaryl-
acrylate derivative to construct the heterocyclic core. The
sequence was completed by an optimized selective catalytic
debenzylation and installation of the anchoring β-propenyl
moiety, by an O-allylation, followed by Claisen rearrangement
and conjugative double bond migration of the resulting 6-allyl-
1H-quinolin-2-one.
The synthesis took place in nine steps and proceeded in
6.1% overall yield, from the known 2-hydroxy-6-nitrobenzalde-
hyde, in turn available in one step from commercial
3-nitrophenol.
Further, an analog of peniprequinolone, lacking its 3,4-
glycol monomethyl ether feature, was also synthesized by
means of a Grubbs II-catalyzed cross metathesis of the 6-allyl-
1H-quinolin-2-one intermediate with 2-methylbut-2-ene.Scheme 5 Syntheses of the target compounds 33 and 36.
program TInit.: 50 °C (3 min); TEnd: 300 °C, at 25 °C min
−1; He
flow: 1.0 mL min−1. Mass spectra were obtained under the fol-
lowing conditions: TInterface: 300 °C; TIon source: 230 °C; Solvent
cut time: 3 min; ionization = 70 eV; range: 60–600 Da. The
microwave-assisted reactions were performed on a CEM Dis-
cover microwave oven.
2-Hydroxy-6-nitrobenzaldehyde (22). A solution of 3-nitro-
phenol (21, 1000 mg, 7.20 mmol) in F3CCO2H (8 mL) was
treated with HMTA (1200 mg, 8.59 mmol) and the mixture was
heated at 90 °C for 12 h. The reaction was poured over ice-
water (25 mL), and the resultant mixture was stirred for 15 min
and then extracted with EtOAc (3 × 40 mL). The organic layers
were washed with brine (20 mL), dried under Na2SO4 and con-
centrated in vacuo. Chromatography of the oily residue
afforded 22 (560 mg, 46%) as a yellow solid, m.p.: 52–54 °C
(lit.: 53–54 °C).20a IR (KBr, ν): 3300, 2955, 2922, 2851, 1693,
1645, 1531, 1454, 1352 and 1284 cm−1. 1H NMR (δ): 7.30
(d, 1H, J = 8.0, H-3), 7.56 (d, 1H, J = 8.0, H-5), 7.63 (t, 1H, J =
8.0, H-4), 10.33 (s, 1H, CHO) and 12.11 (s, 1H, OH). 13C NMR
(δ): 112.4 (C-1), 116.1 (C-5), 124.2 (C-3), 135.9 (C-4), 151.2 (C-6),
163.3 (C-2) and 193.9 (CHO). EI-MS (m/z, rel. int., %): 167
(M+, 7), 149 (39), 137 (61), 120 (25), 119 (25), 109 (19), 107 (13),
92 (59), 91 (32), 93 (11), 81 (100) and 63 (85).
2-Benzyloxy-6-nitrobenzaldehyde (23). K2CO3 (560 mg,
4.00 mmol) was added to a solution of nitro-salicylaldehyde 22
(223 mg, 1.334 mmol) in EtOH (3 mL). The mixture was stirred
for 10 minutes at room temperature; then benzyl chloride
(338 mg, 2.67 mmol) was added dropwise and the mixture was
stirred overnight at 70 °C. After confirming the complete con-
sumption of the starting material, the solvent was evaporated
under reduced pressure and the residue was diluted with brine
(10 mL) and 1 M NaOH (10 mL). The product was extracted
with EtOAc (3 × 20 mL); the combined organic extracts were
washed with water (10 mL), dried over Na2SO4, concentrated
and filtered through a short path of a silica gel to yield the
benzyl ether derivative 23 (342 mg, 99%) as a yellowish oil.38
IR (film, ν): 3734, 3250, 1646, 1626, 1578, 1368, 1340, 1283,
1153, 1081, 1010, 842 and 669 cm–1. 1H NMR (δ): 5.22 (s, 2H,
OCH2Ar), 7.29 (d, 1H, J = 8.1, H-3), 7.36–7.41 (m, 5H, ArH of
benzyl), 7.45 (d, 1H, J = 8.1, H-5), 7.56 (t, 1H, J = 8.1, H-4) and
10.40 (s, 1H, CHO). 13C NMR (δ): 71.6 (OCH2Ar), 115.9 (C-5),
117.6 (C-3), 121.2 (C-1), 127.2 (C-1′ and C-6′), 128.6 (C-4′), 128.9
(C-3′ and C-5′), 133.4 (C-4), 135.0 (C-1′), 148.7 (C-3), 158.8 (C-2)
and 187.6 (CHO).
Ethyl E-3-(2′-benzyloxy-6′-nitrophenyl)acrylate (E-24). A
mixture of aldehyde 23 (265 mg, 1.03 mmol) and ethyl (tri-
phenyl-λ5-phosphanylidene)-acetate (1180 mg, 2.06 mmol) in
dichloromethane (3 mL) was stirred at room temperature for
5 h. Once the complete consumption of the starting material
was confirmed by TLC, the solvent was removed under
reduced pressure and the residue was chromatographed,
affording E-24 (297 mg, 88%) as a yellow solid, m.p.: 80–82 °C.
IR (KBr, ν): 1705, 1521, 1350, 1288, 1273, 1193, 1041, 840 and
746 cm–1. 1H NMR (δ): 1.32 (t, 3H, J = 7.1, OCH2CH3), 4.25
(q, 2H, J = 7.1, OCH2CH3), 5.22 (s, 2H, OCH2Ar), 6.58 (d, 1H,
J = 16.2, CHvCHCO2Et), 7.16 (dd, 1H, J = 2.0 and 8.0, H-3),
Studies are under way to establish the conditions for the 
installation of the characteristic C-3–C-4 monoprotected cis-
diol feature. The results will be communicated in due time.
Experimental section
General information
All the reactions were carried out under dry nitrogen or argon 
atmospheres, employing oven-dried glassware. Anhydrous THF 
and anhydrous CH2Cl2 were obtained from an M. Braun 
solvent purification and dispenser system. Absolute MeOH 
and EtOH were accessed by refluxing the solvents over clean 
Mg/I2 and distilling from the resulting magnesium alkoxides; 
anhydrous 1,2-dichlorobenzene was prepared by a 4 h reflux of 
the solvent over P2O5 followed by atmospheric pressure distilla-
tion. All other reagents were used as received.
The flash column chromatographies were run with Merck’s 
silica gel 60 H, eluting with hexane/EtOAc mixtures, under 
positive pressure and employing gradient of solvent polarity 
techniques.
All new compounds gave single spots on TLC plates (silica 
gel 60 GF254) run in different hexane/EtOAc and EtOAc/EtOH 
solvent systems. The chromatographic spots were detected by 
exposure to 254 nm UV light, followed by spraying with 
ethanolic p-anisaldehyde/sulfuric acid reagent, 1% methanolic 
FeCl3, ninhydrin or Dragendorff reagent (Munier and Mache-
boeuf modification),37 and finally careful heating of the plates 
for improving selectivity.
Apparatus
The melting points were measured on an Ernst Leitz Wetzlar 
model 350 hot-stage microscope and are reported uncorrected. 
The IR spectra were recorded with a Shimadzu Prestige 21 
spectrophotometer, as thin films held between NaCl cells, as 
solid dispersions in KBr disks, or with a Pike ATR accessory.
The 1H NMR spectra were acquired at 300.13 MHz in 
CDCl3, unless noted otherwise, on a Bruker Avance spectro-
meter. Chemical shifts are reported in parts per million on the 
δ scale and J-values are given in hertz. The peak of the residual 
protonated solvent (CHCl3 in CDCl3, δ 7.26) was used as the 
internal standard. The 13C NMR spectra were recorded at 
75.48 MHz on a Bruker Avance spectrometer. The solvent peak 
(CDCl3, δ 77.0) was used as the internal standard. DEPT 135 
and DEPT 90 experiments aided the interpretation and assign-
ment of the fully decoupled 13C NMR spectra. In special cases, 
2D-NMR experiments (COSY, HMBC and HMQC) were also 
employed. Pairs of signals marked with an asterisk (*) indicate 
that their assignments may be exchanged.
The high resolution mass spectra were obtained with a 
Bruker MicroTOF-Q II instrument (Bruker Daltonics, Billerica, 
MA). Detection of the ions was performed in electrospray 
ionization, positive ion mode. The GC-MS experiments were 
carried out with a Shimadzu QP2010 plus instrument. The 
runs were performed in split injection mode (ratio: 50), 
column SPB-1 (30 m × 0.25 mm × 0.25 μm); oven temperature
7.35 (dt, 1H, J = 2.0 and 8.0, H-5), 7.36 (d, J = 8.0, 1H, H-4),
7.38–7.41 (m, 5H, ArH of benzyl) and 7.73 (d, 1H, J =
16.2, CHvCHCO2Et).
13C NMR (δ): 14.3 (OCH2CH3), 60.7
(OCH2CH3), 71.4 (OCH2Ar), 116.3 (C-3), 116.5 (C-5), 118.7
(C-1), 125.9 (CHvCHCO2Et), 127.0 (benzyl), 128.4 (C-4), 128.6
(benzyl), 128.8 (benzyl), 134.3 (CHvCHCO2Et), 135.5 (benzyl),
150.9 (C-6), 157.5 (C-2) and 166.4 (CHvCHCO2Et). HRMS m/z
calcd for C18H18NO5: 328.1185 [M + H]
+; found: 328.1179.
Ethyl Z-3-(2-benzyloxy-6-nitrophenyl)-3-(4′-methoxyphenyl)-
acrylate (26). A mixture of cinnamate ester 24 (245 mg,
0.749 mmol) and Pd(OAc)2 (17 mg, 0.0749 mmol) in MeOH
(3 mL) was vigorously stirred at 80 °C for 30 s; then p-anisidine
diazonium tetrafluoroborate salt (333 mg, 1.50 mmol) pre-
pared under the literature-reported conditions24a was added
into one portion. The reaction was further stirred at 80 °C
until the complete consumption of the starting material was
confirmed by TLC analysis. Then, the reaction mixture was
concentrated under reduced pressure and the residue was
chromatographed to afford the β,β-diphenylacrylate 26
(194 mg, 60%) as a yellow solid, m.p.: 102–104 °C. IR (KBr, ν):
2934, 1717, 1603, 1526, 1508, 1448, 1362, 1269, 1163 and
741 cm–1. 1H NMR (δ): 1.08 (t, 3H, J = 7.1, OCH2CH3), 3.82
(s, 3H, ArOCH3), 3.98 (q, 2H, J = 7.1, OCH2CH3), 5.02 (q, 2H, J =
12.3, OCH2Ar), 6.45 (s, 1H, H-3), 6.85 (d, 2H, J = 8.8, H-11 and
H-13), 7.04 (dd, 2H, J = 2.8 and 6.3, ArH of benzyl), 7.21 (d, 1H,
J = 8.3, H-8), 7.23–7.26 (m, 3H, ArH of benzyl), 7.33 (d, 2H, J =
8.8, H-10 and H-14), 7.45 (t, 1H, J = 8.3, H-7) and 7.72 (d, 1H,
J = 8.3, H-6). 13C NMR (δ): 14.0 (OCH2CH3), 55.3 (OCH3), 60.0
(OCH2CH3), 70.8 (OCH2Ar), 113.9 (C-11 and C-13), 116.0 (C-3),
116.4 (C-6),* 117.0 (C-8),* 124.9 (C-1), 126.9 (2C, benzyl), 127.9
(C-4′), 128.4 (2C, benzyl), 128.7 (C-10 and C-14), 129.1 (C-7),
130.6 (C-9), 136.0 (benzyl), 149.0 (C-7), 149.2 (C-6), 155.9 (C-2),
160.8 (C-4′) and 165.6 (CO2Et). EI-MS (m/z, rel. int., %): 433
(M+, 1), 416 (10), 151 (58), 150 (100), 133 (20), 122 (47), 121
(21), 115 (29), 107 (22), 106 (30), 105 (31), 104 (20), 103 (59), 94
(36), 93 (28), 91 (56) and 77 (92). HRMS m/z calcd for
C25H24NO6 434.1604 [M + H]
+; found: 434.1598.
5-Benzyloxy-4-(4′-methoxyphenyl)-1H-quinolin-2-one (19).
(benzyl), 140.8 (C-8a), 152.3 (C-4), 156.4 (C-5), 158.8 (C-4′)
and 162.9 (C-2). HRMS m/z calcd for C23H19NNaO3: 380.1257
[M + Na]+; found: 380.1245.
5-Hydroxy-4-(4′-methoxyphenyl)-1H-quinolin-2-one (27). Method
A: the benzyloxy derivative 19 (62 mg, 0.174 mmol) was added
to a stirred suspension of 10% Pd/C (3 mg) in a 1 : 1 mixture of
EtOH : EtOAc (2 mL), and cooled to 0 °C in an ice bath. The
system was placed under a hydrogen atmosphere (1 atm.) and
stirred for 4 h. Then, the reaction was diluted with EtOAc
(10 mL) and filtered through Celite. The filtrate was dried over
Na2SO4, concentrated in vacuo and chromatographed,
affording the 5-hydroxy-1H-quinolin-2-one 27 (41 mg, 89%) as
a tan crystalline solid, m.p.: 260–262 °C (hexanes–EtOAc).
IR (KBr, ν): 2928, 2369, 1630, 1607, 1508, 1356, 1281, 1244 and
833 cm–1. 1H NMR (δ): 3.89 (s, 3H, OCH3), 5.59 (s, 1H, N–H),
6.41 (s, 1H, H-3), 6.64 (dd, 1H, J = 0.7 and 8.3, H-6), 6.98 (dd,
1H, J = 0.7 and 8.3, H-8), 7.06 (d, 2H, J = 8.7, H-3′ and H-5′),
7.39 (t, 1H, J = 8.3, H-7), 7.41 (d, 2H, J = 8.7, H-2′ and H-6′) and
8.53 (s, 1H, OH). 13C NMR (δ): 55.5 (OCH3), 108.3 (C-4a), 108.7
(C-6), 110.4 (C-8), 115.0 (C-3′ and C-5′), 121.8 (C-3), 129.4 (C-2′
and C-6′), 129.6 (C-1′), 132.1 (C-7), 139.9 (C-8a), 150.2 (C-4),
154.3 (C-5), 160.7 (C-12), and 163.0 (C-2). EI-MS (m/z, rel. int.,
%): 357 (M+, 6), 91 (100), 73 (14) and 71 (18). HRMS m/z calcd
for C16H14NO3: 268.0974 [M + H]
+; found: 268.0968.
Method B: a magnetically stirred mixture of compound 26
(24 mg, 0.055 mmol) and 10% Pd/C (1 mg) in anhydrous
MeOH (2 mL) was exposed to a hydrogen atmosphere (1 atm.)
for 2 h at room temperature. Then, the suspension was filtered
through a short pad of Celite and the filtrate was concentrated
under reduced pressure. The ensuing light yellow solid was
subjected to flash chromatography, affording compound 27
(4 mg, 30%) as a brownish crystalline solid. The spectral data
of this product were in full agreement with those recorded for
the product obtained through Method A.
5-Allyloxy-4-(4′-methoxyphenyl)-1H-quinolin-2-one (31). A
solution of 27 (316 mg, 1.183 mmol) in absolute EtOH (4 mL)
was treated with K2CO3 (199 mg, 1.420 mmol). The resulting
suspension was stirred at room temperature for 10 min; then
allyl bromide (171 mg, 1.420 mmol) was added into one
portion and the reaction was heated under reflux for 4 h. After
confirming the complete consumption of the starting material
by TLC, the reaction mixture was treated with a 1 M solution of
HCl (10 mL) and the products were extracted with EtOAc
(3 × 15 mL). The combined extracts were dried with Na2SO4
and concentrated under reduced pressure. The residue was
subjected to flash chromatography, affording compound 31
(235 mg, 65%) as a colorless solid, m.p.: 210–212 °C (CH2Cl2).
IR (ATR, ν): 3734, 3250, 1646, 1626, 1578, 1368, 1340, 1283,
1153, 1081, 1010, 842 and 669 cm–1. 1H NMR (DMSO-d6, δ):
3.77 (s, 3H, OCH3), 4.25 (d, J = 5.2, 2H, CH2vCH–CH2–Ar),
4.79 (d, J = 18.7, 1H, CHtransvCH–CH–Ar), 4.90 (d, J = 10.7, 1H,
CHcisvCH–CH2–Ar), 5.36 (ddd, J = 5.2, 10.7 and 18.7, 1H,
CH2vCH–CH2–Ar), 5.59 (s, 1H, NH), 6.41 (s, 1H, H-3), 6.66
(d, 1H, J = 8.2, H-6), 6.89 (d, 2H, J = 8.5, H-3′ and H-5′), 6.97
(d, 1H, J = 8.2, H-8), 7.17 (d, 2H, J = 8.5, H-2′ and H-6′), and
7.41 (t, 1H, J = 8.2, H-7). 13C NMR (DMSO-d6, δ): 55.5 (OCH3),
Clean iron turnings (206 mg, 3.69 mmol) were added to a 
stirred solution of β,β-diphenylacrylate 26 (200 mg, 
0.461 mmol) in glacial AcOH (2 mL) pre-heated at 110 °C. Stir-
ring was continued for 18 h; then the solution was brought to 
room temperature, and the precipitate was filtered off and 
washed with EtOAc (10 mL). The combined organic solutions 
were evaporated under reduced pressure and the residue was 
chromatographed to furnish 19 (120 mg, 74%) as a brown 
solid, m.p.: 207–209 °C. IR (KBr, ν): 3734, 3250, 1646, 1626, 
1578, 1368, 1340, 1283, 1153, 1081, 1010, 842 and 669 cm–1. 
1H NMR (δ): 3.62 (s, 3H, OCH3), 4.69 (s, 2H, OCH2Ar), 6.28 
(s, 1H, H-3), 6.57 (d, 2H, J = 8.5, H-3′ and H-5′), 6.57 (d, J = 8.3, 
1H, H-6), 6.74 (d, 2H, J = 8.5, H-2′ and H-6′), 6.98 (d, 1H, J = 
8.3, H-8), 7.03–7.14 (m, 5H, ArH of benzyl), 7.30 (t, 1H, J = 8.3,
H-7) and 11.71 (s, 1H, N–H). 13C NMR (δ): 54.9 (OCH3), 70.5 
(OCH2Ar), 105.1 (C-6), 109.5 (C-8), 110.2 (C-4a), 112.5 (C-3′ and 
C-5′), 122.4 (C-3), 127.2 (C-2′ and C-6′), 127.5 (benzyl), 127.9 
(benzyl), 128.6 (benzyl), 131.1 (C-7), 134.0 (C-1′), 135.7
temperature for 20 h. After the complete consumption of the
starting material was confirmed by TLC, the reaction was
poured on H2O (10 mL), and the product was extracted with
Et2O (3 × 10 mL). The organic phase was washed with NaHCO3
(10 mL), brine (10 mL), and H2O (10 mL). The combined
organic layers were dried (Na2SO4) and concentrated under
reduced pressure. Chromatography of the residue afforded the
compound 35 (120 mg, 0.299 mmol) as a pale yellow solid,
m.p.: 172–174 °C (CH2Cl2). IR (KBr, ν): 2930, 1666, 1661, 1514,
1371, 1101, 876 and 833 cm–1. 1H NMR (δ): 1.26 (s, 9H,
C–(CH3)3), 3.28 (d, 2H, J = 6.5, CH2–CHvCH2), 3.88 (s, 3H,
OCH3), 5.03 (m, 1H, CHcisvCH–CH2–Ar), 5.08 (m, 1H,
CHtransvCH–CH2–Ar), 5.85 (ddd, 1H, J = 6.5, 9.4 and 16.2,
CH2vCH–CH2–Ar), 6.54 (s, 1H, H-3), 6.97 (d, 2H, J = 8.6, H-3′
and H-5′), 7.32 (d, 2H, J = 8.6, H-2′ and H-6′), 7.36 (d, 1H, J =
8.6, H-8) and 7.42 (d, 1H, J = 8.6, H-7). 13C NMR (δ): 27.3
[C–(CH3)3], 33.7 (CH2vCH–CH2–Ar), 55.3 (OCH3), 83.3
[C–(CH3)3], 104.3 (C-6), 113.4 (C-9), 113.6 (C-3′ and C-5′), 115.0
(C-8), 116.8 (CH2vCH–CH2–Ar), 124.0 (C-3), 127.5 (C-3), 131.8
(C-4a), 132.5 (C-2′ and C-6′), 135.4 (CH2vCH–CH2–Ar), 138.8
(C-8a), 143.2 (C-5), 150.4 [N-(CvO)–O], 151.0 (C-4), 159.4 (C-4′)
and 163.2 (C-2). HRMS m/z calcd for C24H25NNaO5: 430.1625
[M + Na]+; found: 430.1610.
tert-Butyl 5-hydroxy-4-(4′-methoxyphenyl)-2-oxo-6-propenyl-
1H-quinoline-1-carboxylate (36). To a solution of allyl deriva-
tive 35 (10 mg, 0.024 mmol) in EtOH (1 mL) was added
RhCl3·3H2O (2.13 mg, 0.0082 mmol). The resulting mixture
was stirred for 31 h at room temperature. Then, the reaction
was filtered through a silica-pad with EtOAc as an eluent. The
filtrate was concentrated under reduced pressure to afford
compound 36 (5 mg, 50%) as a white solid, m.p.: 139–140 °C
(CH2Cl2). IR (KBr, ν): 3690, 2928, 2853, 2370, 1751, 1663, 1549,
1508, 1458, 1248, 1151 and 833 cm–1. 1H NMR (δ): 1.18 [s, 9H,
C–(CH3)3], 1.78 (d, 3H, J = 6.3, CH3–CHvCH–Ar), 3.80 (s, 3H,
OCH3), 6.19 (dd, J = 6.3 and 15.7, 1H, CH3–CHvCH–Ar),
6.36 (d, J = 15.7, 1H, CH3–CHvCH–Ar), 6.53 (s, 1H, H-3),
6.95 (d, 2H, J = 8.6, H-3′ and H-5′), 7.19 (d, 2H, J = 8.6, H-2′
and H-6′), 7.28 (d, 1H, J = 8.8, H-7) and 8.73 (d, 1H, J =
8.8, H-8). 13C NMR (DMSO-d6, δ): 18.6 (CH3–CHvCH–Ar),
26.8 [C–(CH3)3], 55.1 (OCH3), 82.5 [C–(CH3)3], 112.3 (C-6),
113.2 (C-3′ and C-5′), 114.2 (C-7), 123.2 (CH3–CHvCH–Ar),
124.3 (C-3), 124.5 (C-4a), 127.9 (CH3–CHvCH–Ar), 128.5
(C-8), 129.1 (C-2′ and C-6′), 131.4 (C-9), 139.5 (C-8a), 143.2
(N(CvO)–O), 149.3 (C-4), 149.8 (C-5), 158.8 (C-4′) and 160.4
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69.2 (CH2vCH–CH2–Ar), 108.3 (C-4a), 108.7 (C-6), 110.4 (C-8), 
115.0 (C-3′ and C-5′), 117.1 (CH2vCH–CH–Ar), 121.8 (C-3), 
129.4 (C-2′ and C-6′), 129.6 (C-9), 132.1 (C-7), 132.8 (CH2vCH–
CH–Ar), 139.9 (C-8a), 150.2 (C-4), 154.3 (C-5), 160.7 (C-12) and 
163.0 (C-2). HRMS m/z for C19H18NO3: 308.1287 [M + H]+; 
found: 308.1281.
6-Allyl-5-hydroxy-4-(4′-methoxyphenyl)-1H-quinolin-2-one 
(32). The O-allyl derivative (31) (200 mg, 0.651 s mmol) was 
dissolved in 1,2-dichlorobenzene (4 mL) and the solution was 
placed in a sealed tube. The mixture was heated in a micro-
wave reactor (300 W) at 190 °C for 120 min. The crude product 
was purified by flash chromatography on a silica gel to give 32 
(0.150 g, 75%) as a colorless oil, m.p.: >300 °C (EtOAc). 
IR (KBr, ν): 2928, 2369, 1630, 1607, 1508, 1356, 1281, 1244 and 
833 cm–1. 1H NMR (δ): 3.33 (d, 2H, J = 6.5, H-1′), 3.89 (s, 3H, 
OCH3), 4.99 (d, J = 15.7, 1H, CHcisvCH–CH2–Ar), 5.04 (d, J = 
17.8, 1H, CHtransvCH–CH2–Ar), 5.93 (ddd, 1H, J = 6.5, 15.7 
and 17.8, CH2vCH–CH2–Ar), 6.41 (s, 1H, H-3), 6.99 (d, 1H, J = 
8.3, H-8), 7.06 (d, 2H, J = 8.7, H-3′ and H-5′), 7.30 (d, 1H, J = 
8.3, H-7) and 7.40 (d, 2H, J = 8.7, H-2′ and H-6′). 13C NMR (δ): 
34.0 (CH2vCH–CH2–Ar), 55.4 (OCH3), 108.2 (C-4a), 108.4 
(C-8), 115.0 (C-3′ and C-5′), 115.6 (CH2vCH–CH2–Ar), 120.6 
(C-8a), 121.9 (C-3), 129.5 (C-2′ and C-6′), 129.7 (C-1′), 133.3 
(C-7), 136.5 (CH2vCH–CH2–Ar), 138.6 (C-6), 150.2 (C-4), 151.3 
(C-5), 160.7 (C-4′) and 163.1 (C-2). HRMS m/z calcd for 
C19H18NO3 308.1287 [M + H]+; found: 308.1281.
5-Hydroxy-4-(4′-methoxyphenyl)-6-(3-methyl-but-2-enyl)-1H-
quinolin-2-one (33). To a stirred solution of the allyl derivative 
32 (12 mg, 0.039 mmol) in anhydrous CH2Cl2 (0.5 mL) was 
added the Grubbs II catalyst (1.6 mg, 5 mol%). Then, 
2-methyl-but-2-ene (27.4 mg, 0.391 mmol) was added drop-
wise, the system was sealed and the mixture was heated to 
reflux. After being stirred for 2 h, the reaction was cooled to rt 
and filtered through a silica plug, washing with EtOAc 
(20 mL). The filtrate was concentrated under reduced pressure 
to afford 33 (10 mg, 77%) as a brownish solid, m.p.: 
222–224 °C (EtOAc). IR (KBr, ν): 3480, 2926, 2359, 1645, 1634, 
1607, 1512, 1454, 1373, 1248, 1178, 1032 and 833 cm–1. 
1H NMR (δ): 1.67 (s, 3H, C–CH3), 1.71 (s, 3H, C–CH3), 3.25 
[d, 1H, J = 6.7, CH2–CHvC(CH3)2], 3.89 (s, 3H, OCH3), 5.24 
[bs, 1H, CH2–CHvC(CH3)2], 5.67 (bs, 1H, –NH), 6.39 (s, 1H, 
H-3), 6.94 (d, 1H, J = 8.2, H-8), 7.07 (d, 2H, J = 8.3, H-3′ and 
H-5′), 7.29 (d, 1H, J = 8.2, H-7), 7.40 (d, 2H, J = 8.3, H-2′ and
H-6′) and 11.91 (s, 1H, OH). 13C NMR (δ): 17.8 (C–CH3), 25.7 
(C–CH3), 28.2 [CH2–CHvC(CH3)2], 55.4 (OCH3), 108.2 (C-8), 
115.0 (C-3′ and C-5′), 122.1 (C-3), 122.2 [CH2–CHvC(CH3)2], 
127.3 (C-4a), 128.7 (C-4), 129.5 (C-2′ and C-6′), 129.9 (C-9), 
132.9 (C-7), 133.2 [CH2–CHvC(CH3)2], 138.2 (C-8a), 150.2 
(C-6), 151.3 (C-5), 160.6 (C-4′) and 163.0 (C-2). HRMS m/z calcd 
for C21H22NO3: 336.1577 [M + H]+; found: 336.1594.
tert-Butyl 6-allyl-5-hydroxy-4-(4′-methoxyphenyl)-2-oxo-2H-
quinoline-1-carboxylate (35). To a solution of 32 (146 mg, 
0.475 mmol) in anhydrous CH2Cl2 (2 mL) was added an-
hydrous Et3N (144 mg, 1.425 mmol) and DMAP (17.3 mg, 
0.142 mmol). Then, Boc2O (310 mg, 1.425 mmol) was added 
into one portion and the resulting mixture was stirred at room
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